Ország: Szingapúr
Nyelv: angol
Forrás: HSA (Health Sciences Authority)
Methylphenidate 23.34mg eqv Methylphenidate HCl
JOHNSON & JOHNSON INTERNATIONAL (SINGAPORE) PTE LTD
N06BA04
27mg
TABLET, FILM COATED
Methylphenidate 23.34mg eqv Methylphenidate HCl 27mg
ORAL
Prescription Only
JANSSEN-CILAG MANUFACTURING, LLC
ACTIVE
2003-09-26
1 PRODUCT NAME CONCERTA ® (methylphenidate hydrochloride) DOSAGE FORMS AND STRENGTHS Extended-release tablets: 18 MG TABLET Capsule-shaped yellow tablet with “alza 18” printed on one side in black ink. Each tablet contains 18 mg of methylphenidate hydrochloride. 27 MG TABLET Capsule-shaped gray tablet with “alza 27” printed on one side in black ink. Each tablet contains 27 mg of methylphenidate hydrochloride. 36 MG TABLET Capsule-shaped white tablet with “alza 36” printed on one side in black ink. Each tablet contains 36 mg of methylphenidate hydrochloride. 54 MG TABLET Capsule-shaped brownish-red tablet with “alza 54” printed on one side in black ink. Each tablet contains 54 mg of methylphenidate hydrochloride. For excipients, see _List of Excipients_. CLINICAL INFORMATION INDICATIONS CONCERTA ® is indicated for the treatment of Attention Deficit Hyperactivity Disorder (ADHD). The efficacy of CONCERTA ® in the treatment of ADHD was established in controlled trials of children and adolescents aged 6 to 17 and adults aged 18 to 65 who met DSM-IV criteria for ADHD. A diagnosis of Attention Deficit Hyperactivity Disorder (ADHD; DSM-IV) implies the presence of hyperactive-impulsive or inattentive symptoms that caused impairment and were present before age 7 years. The symptoms must cause clinically significant impairment, eg, in social, academic, or occupational functioning, and be present in two or more settings, eg, school (or work) and at home. The symptoms must not be better accounted for by another mental disorder. For the Inattentive type, at least six of the followi Olvassa el a teljes dokumentumot
1 PRODUCT NAME CONCERTA ® (methylphenidate hydrochloride) DOSAGE FORMS AND STRENGTHS Extended-release tablets: 18 MG TABLET Capsule-shaped yellow tablet with “alza 18” printed on one side in black ink. Each tablet contains 18 mg of methylphenidate hydrochloride. 27 MG TABLET Capsule-shaped gray tablet with “alza 27” printed on one side in black ink. Each tablet contains 27 mg of methylphenidate hydrochloride. 36 MG TABLET Capsule-shaped white tablet with “alza 36” printed on one side in black ink. Each tablet contains 36 mg of methylphenidate hydrochloride. 54 MG TABLET Capsule-shaped brownish-red tablet with “alza 54” printed on one side in black ink. Each tablet contains 54 mg of methylphenidate hydrochloride. For excipients, see _List of Excipients_ . CLINICAL INFORMATION INDICATIONS CONCERTA ® is indicated for the treatment of Attention Deficit Hyperactivity Disorder (ADHD). The efficacy of CONCERTA ® in the treatment of ADHD was established in controlled trials of children and adolescents aged 6 to 17 and adults aged 18 to 65 who met DSM-IV criteria for ADHD. A diagnosis of Attention Deficit Hyperactivity Disorder (ADHD; DSM-IV) implies the presence of hyperactive-impulsive or inattentive symptoms that caused impairment and were present before age 7 years. The symptoms must cause clinically significant impairment, eg, in social, academic, or occupational functioning, and be present in two or more settings, eg, school (or work) and at home. The symptoms must not be better accounted for by another mental disorder. For the Inattentive type, at least six of the following symptoms must have persisted for at least 6 months, lack of attention to details/careless mistakes; lack of sustained attention; poor listener; failure to follow through on tasks; poor organization; avoids tasks requiring sustained mental effort; loses things; easily distracted; forgetful. For the Hyperactive-Impulsive Type, at least six of the following symptoms must have persisted for at least 6 months; fidgeting/squirming; Olvassa el a teljes dokumentumot